| Autor: |
Joshua A. Hill, Michael J. Martens, Jo-Anne H. Young, Kavita Bhavsar, Jianqun Kou, Min Chen, Lik Wee Lee, Aliyah Baluch, Madhav V. Dhodapkar, Ryotaro Nakamura, Kristin Peyton, Zainab Shahid, Paul Armistead, Peter Westervelt, John McCarty, Joseph McGuirk, Mehdi Hamadani, Susan DeWolf, Kinga Hosszu, Elad Sharon, Ashley Spahn, Amir A. Toor, Stephanie Waldvogel, Lee M. Greenberger, Jeffery J. Auletta, Mary M. Horowitz, Marcie L. Riches, Miguel-Angel Perales |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
EClinicalMedicine, Vol 59, Iss , Pp 101983- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2589-5370 |
| DOI: |
10.1016/j.eclinm.2023.101983 |
| Popis: |
Summary: Background: The optimal timing for SARS-CoV-2 vaccines within the first year after allogeneic hematopoietic cell transplant (HCT) is poorly understood. Methods: We conducted a prospective, multicentre, observational study of allogeneic HCT recipients who initiated SARS-CoV-2 vaccinations within 12 months of HCT. Participants were enrolled at 22 academic cancer centers across the United States. Participants of any age who were planning to receive a first post-HCT SARS-CoV-2 vaccine within 12 months of HCT were eligible. We obtained blood prior to and after each vaccine dose for up to four vaccine doses, with an end-of-study sample seven to nine months after enrollment. We tested for SARS-CoV-2 spike protein (anti-S) IgG; nucleocapsid protein (anti-N) IgG; neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains; and SARS-CoV-2-specific T-cell receptors (TCRs). The primary outcome was a comparison of anti-S IgG titers at the post-V2 time point in participants initiating vaccinations |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
